Validation and analysis of prognostic scoring systems for critically ill patients with cirrhosis admitted to ICU by Campbell, Joseph et al.
RESEARCH Open Access
Validation and analysis of prognostic
scoring systems for critically ill patients
with cirrhosis admitted to ICU
Joseph Campbell1* , Joanne McPeake1, Martin Shaw2, Alex Puxty3, Ewan Forrest4, Charlotte Soulsby1,
Philp Emerson1, Sam J. Thomson5, Tony M. Rahman6,7, Tara Quasim1 and John Kinsella1
Abstract
Introduction: The number of patients admitted to ICU who have liver cirrhosis is rising. Current prognostic scoring
tools to predict ICU mortality have performed poorly in this group. In previous research from a single centre, a
novel scoring tool which modifies the Child-Turcotte Pugh score by adding Lactate concentration, the CTP + L
score, is strongly associated with mortality. This study aims to validate the use of the CTP + L scoring tool for
predicting ICU mortality in patients admitted to a general ICU with cirrhosis, and to determine significant predictive
factors for mortality with this group of patients. This study will also explore the use of the Royal Free Hospital (RFH)
score in this cohort.
Methods: A total of 84 patients admitted to the Glasgow Royal Infirmary ICU between June 2012 and Dec 2013
with cirrhosis were included. An additional cohort of 115 patients was obtained from two ICUs in London
(St George’s and St Thomas’) collected between October 2007 and July 2009. Liver specific and general ICU
scoring tools were calculated for both cohorts, and compared using area under the receiver operating
characteristic (ROC) curves. Independent predictors of ICU mortality were identified by univariate analysis. Multivariate
analysis was utilised to determine the most predictive factors affecting mortality within these patient groups.
Results: Within the Glasgow cohort, independent predictors of ICU mortality were identified as Lactate (p < 0.001),
Bilirubin (p = 0.0048), PaO2/FiO2 Ratio (p = 0.032) and PT ratio (p = 0.012). Within the London cohort, independent
predictors of ICU mortality were Lactate (p < 0.001), PT ratio (p < 0.001), Bilirubin (p = 0.027), PaO2/FiO2 Ratio
(p = 0.0011) and Ascites (p = 0.023). The CTP + L and RFH scoring tools had the highest ROC value in both cohorts
examined.
Conclusion: The CTP + L and RFH scoring tool are validated prognostic scoring tools for predicting ICU mortality in
patients admitted to a general ICU with cirrhosis.
Introduction
The prevalence of liver disease in Scotland has been
increasing over the last 30 years. Mortality due to liver
disease is one of the few causes of death that is increas-
ing [1]. There is a similar picture in England and Wales,
with liver disease being the fifth most common cause
of mortality after heart disease, cancer, stroke, and
respiratory disease. This is in contrast to most Western
European countries, which have seen a decline [1, 2].
Liver disease accounts for an increasing proportion of
Intensive Care Unit (ICU) and hospital admissions. Ad-
missions rose by 71 % in male patients and 43 % in fe-
male patients between 1990 and 2003. This change has
been mainly attributed to alcohol, which accounted for
85 % of liver disease deaths in 2007 [3]. Overall, patients
with cirrhosis account for 15 % of Glasgow Royal Infirm-
ary ICU admissions, and 3.3 % of ICU admissions in St
George’s and St Thomas’ Hospitals. Patients with liver dis-
ease admitted to ICU have poor outcomes and a complex
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disease process. Mortality in these patients is widely docu-
mented in literature, with a meta-analysis of seventeen pa-
pers in 2010 showing the weighted mean ICU and
hospital mortality to be 45 % and 58 %, respectively [4, 5].
There are currently no validated prognostic scoring
tools to predict ICU outcome in patients with cirrhotic
liver disease within the general ICU setting that can be
calculated quickly at a patient’s bedside. Existing hepatic
scoring tools are designed for a specific use, for ex-
ample, the Child-Turcotte Pugh (CTP) score was de-
signed to predict mortality following surgical treatment of
oesophageal varices, and the United Kingdom model for
end-stage liver disease (UKELD) was designed to assess
patients for transplant in the UK [6, 7].
In research conducted at Glasgow Royal Infirmary,
existing scoring tools (the CTP, UKELD, model of end-
stage liver disease (MELD), Glasgow alcoholic hepatitis
score (GAHS), sequential organ failure assessment
(SOFA), the acute physiology and chronic health evalu-
ation II (APACHE II), and the chronic liver failure-
sequential organ failure assessment score (CLIF-SOFA))
did not reach the level of clinical usefulness based on
receiver operating characteristic (ROC) curve analysis of
an area under the curve (AUC) of ≥0.8 [8-10]. Therefore,
these existing tools may not be clinically useful for pre-
dicting ICU mortality. Analysis of this cohort found lac-
tate, bilirubin, ascites, and prothrombin time (PT) ratio
as independent predictors of outcome [11]. Other pub-
lished studies have shown promising results for predict-
ing outcome in patients with cirrhosis using the SOFA
and MELD scoring tools, and have also demonstrated
that the current CTP score is not the most effective tool
for predicting outcome in patients with cirrhosis [12, 13].
The relationship between blood lactate concentration
on admission to the ICU and mortality in patients with
cirrhosis is widely demonstrated within the literature
[14-17]. Despite this, only one existing liver-specific
scoring tool, the Royal Free Hospital score (RFH) in-
cludes lactate, which is validated for use in a tertiary
hepatic treatment centre [18]. As a result, in a previous
study [11] lactate was incorporated into an existing scor-
ing tool, the CTP, to produce two novel tools. The CTP
score was chosen due to its categorical variables that can
easily be calculated at a patient’s bedside. One scoring
tool (CTP-L) splits the lactate into bands and awards 1,
2 or 3 points, which is similar to the other variables in
the CTP score. The other tool (CTP + L) adds the raw
value of lactate (mmol/L) onto the existing CTP score.
These unvalidated tools performed well in a single co-
hort of patients, but results need to be validated in pa-
tients from another centre to demonstrate the usefulness
of the scoring tool [11]. This study aims to validate these
newly created scoring tools as prognostic measures of
ICU outcome using data obtained from another ICU
centre, and to determine the most predictive factors for
predicting ICU outcome within these cohorts.
Methods
Data collection for the previous study took place be-
tween June 2012 and May 2013, and 59 patients were re-
cruited from the Glasgow Royal Infirmary (GRI) ICU.
This is a 20-bed facility with a large gastroenterology
unit, but is not a tertiary hepatic transplant centre [11].
An additional cohort of 25 patients from the GRI was
recruited by extension of the data collection period by
6 months, giving a combined total of 84 patients. Data
were collected as part of routine data collection within
the department and no additional consent was required.
Ethics approval was granted by the Local Research
Ethics Committee (West of Scotland Research Ethics
Committee, approved 20 March 2012, REC reference;
12/WS/0039, Chair; Dr Gregory Ofili) for the original
data collection and the extension of data collection.
Inclusion was based on the presence of cirrhosis on
admission to the ICU in any patient over 18 years old.
Cirrhosis was diagnosed either histologically following
biopsy or clinically by evidence of portal hypertension
and one of the following: ascites, encephalopathy or
oesophageal varices. Diagnosis was confirmed by an in-
dependent clinician.
Clinical and demographic data were obtained from
patients’ electronic records (CareVue, Philips IntelliVue
Clinical Information Portfolio (ICIP) Revision D.03,
Warrick, Naik, Avis, Fletcher, Franklin, Inwald 2011) and
WardWatcher (Critical Care Audit Limited, Yorkshire).
These are validated and complete clinical information sys-
tems [19]. First available clinical test results after admis-
sion to the ICU were recorded and used to calculate
scores using all scoring tools. Clinical and biochemical
data collected included sodium, potassium, urea, arterial
lactate, creatinine, white cell count, bilirubin, PT ratio,
albumin, platelets, arterial partial pressure of oxygen
(PaO2), arterial partial pressure of carbon dioxide
(PaCO2), PaO2/ inspired oxygen fraction (FiO2) ratio
(calculated from the arterial gas sample), Glasgow coma
scale (GCS), mean arterial blood pressure (MAP), nor-
adrenaline dose, ascites and encephalopathy grade. Demo-
graphic information was also recorded relating to: age,
gender, reason for admission, and Scottish Index of Mul-
tiple Deprivation (SIMD). The SIMD scores deprivation
based on postcode and takes into account employment,
income, health, education and crime, and is only applic-
able within Scotland [20]. The Indices of Deprivation is a
deprivation score that is valid within England, but the re-
quired information was not available at the time of data
collection so the score is not included [21]. West Haven
criteria encephalopathy scores and ascites scores were
collected pre-intubation in all patients.
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A second previously published cohort of 115 ICU
patients with cirrhosis was obtained from St Thomas’
Hospital and St George’s Hospital in London. Data
were collected over a period of 20 months between
31 October 2007 and 1 July 2009. These patients were
recruited for a demographic study in cirrhotic patients
within a general ICU population. Scoring tools for these
patients were recalculated based on raw data[5].
Both general ICU and liver-specific scoring tools were
used. The general ICU scoring tools calculated were the
APACHE II and the SOFA score [22, 23]. Liver-specific
scoring tools used were the CTP, UKELD, MELD, CLIF-
SOFA and the RFH score [6, 7, 18, 24, 25].
Of the two new scoring tools, CTP-L and CTP + L,
the latter had achieved a higher AUC on ROC curve
analysis in the cohort upon which it was designed. As a
result, this was the only scoring tool used [11]. A break-
down for the calculation of the CTP + L score can be
seen in Table 1. The GRI data are referred to as the
Glasgow dataset, and the St Thomas’ and St George’s
data are referred to as the London dataset.
Within the Glasgow data, encephalopathy scores were
collected prospectively pre-intubation in all patients to
record accurate values. In other studies, including the
data from the London dataset, the encephalopathy score
was presumed to be 2, as pre-intubation scores were not
available [5]. To test if the collection of pre-intubation
encephalopathy scores was necessary, the Glasgow data-
set was modified to compare the CTP score with correct
encephalopathy, with the CTP score excluding encephal-
opathy scores.
Statistical analysis
Univariate analysis was performed to identify variables
significantly related to ICU outcome. The Welch inde-
pendent samples t test was performed for continuous
parametric data, and the Mann-Whitney U test was
used for non-parametric continuous data. Pearson’s
Chi squared test with Yates’ continuity correction (where
appropriate) or Fisher’s exact test for count data were used
for categorical data. All assumptions for statistical tests
were met and p <0.05 was considered statistically signifi-
cant. All missing data were kept blank.
Scoring tools were applied to both datasets, and com-
pared using the AUC and optimum cutoff point deter-
mined by the Youden’s index from ROC curves. Statistical
models were produced by binary logistic regression for
individual variables in both datasets against ICU mor-
tality, with model selection based on analysis of variance
(ANOVA) and Akaike information criterion (AIC) values.
The optimum cut point from ROC curves produced for
models was used to predict outcomes in the other dataset,
and goodness-of-fit was compared using the Chi squared
test and the phi coefficient. ROC curves were directly
compared using DeLong’s test for correlated ROC curves
and the Chi squared test. An independent statistician
provided assistance with the analysis in this study. Sta-
tistical analysis was performed using RStudio version
0.98.493 (R Foundation for Statistical Computing: Vienna,
Austria) [26-28].
Results
There were 84 patients from the Glasgow dataset and
115 patients from the London dataset initially included
in the analysis. During model selection, five patients
from the Glasgow dataset and one patient from the
London dataset were excluded from subsequent data
analysis due to missing values, leaving 79 and 114 pa-
tients in each group, respectively.
Univariate analysis of the Glasgow dataset demon-
strated that significant predictors of mortality were
lactate (p <0.001), bilirubin (p = 0.0048), PaO2/FiO2 ratio
(p = 0.032), PT ratio (p = 0.012). Mean age of patients in
the Glasgow dataset was 50 years, and 66 % of patients
were from the most deprived category of the SIMD. A
summary of patient data collected and univariate analysis
results can be seen in Table 2.
Univariate analysis of the London dataset showed
that significant predictors of mortality were PT ratio
(p <0.001), lactate (p <0.001), PaO2/FiO2 ratio (p =
0.0011), bilirubin (p = 0.027), and the presence of asci-
tes (p = 0.023). Mean age for patients in the London
dataset was similar to the Glasgow dataset at 51 years.
A summary of the London dataset patient data can
be seen in Table 3.
The mortality rates in the Glasgow dataset were
30 % for ICU and 46 % for hospital, compared with
the London dataset with 37 % ICU and 46 % hospital
mortality. Mean APACHE II scores for the Glasgow
and London datasets were 23.5 and 16.9, respect-
ively, and the mean SOFA scores were 9.7 and 6.4,
respectively.
Table 1 Calculation of the Child-Turcotte Pugh + lactate (CTP + L)
score
Variable 1 Point 2 Points 3 Points
Bilirubin (μmol/L) <34 34 50 >50
Albumin (g/L) >35 28–35 <28
INR (or PT ratio) <1.7 1.71–2.30 >2.3
Ascites grade None Mild Severe
Encephalopathy grade None Grade I/II Grade III/IV
Serum arterial lactate Addition of value in mmol/L to score
obtained from above categories
1, 2 or 3 points are awarded for the five categories below, which form the CTP
score. The serum arterial lactate concentration is added to the CTP score to form
the CTP + L score. INR international normalized ratio, PT prothrombin time
Campbell et al. Critical Care  (2015) 19:364 Page 3 of 9
Validation of CTP + L
All scoring tools were recalculated for both the Glasgow
and London datasets. Within the Glasgow cohort, the
RFH scoring tool performed the most accurately
(AUC = 0.84), with the CTP + L performing to a similar
level (AUC= 0.83). The original CTP score was the least
predictive of ICU mortality (AUC= 0.67). CTP + L and
RFH scores were the only scores to reach the level of clin-
ical usefulness (AUC > = 0.8) within the Glasgow dataset.
Comparison of the AUC of scoring tools applied to each
dataset can be seen in Table 4.
On the London dataset the RFH score performed most
accurately (AUC = 0.77), with the CTP + L score per-
forming to a similar level (AUC = 0.75). The original
CTP score was again the least predictive of ICU mortality
(AUC= 0.68). No scoring tool reached the clinically useful
AUC of 0.8 in this dataset.
Binary logistic regression models
As none of the existing scoring tools applied to the
London dataset reached the level of clinical usefulness,
the raw data were analysed to find the optimum model
for predicting ICU outcome. Statistical models were pro-
duced by binary logistic regression using the Glasgow
dataset, and the optimum model for predicting ICU
mortality was determined by ROC curve analysis. The
highest AUC from ROC curve analysis in the Glasgow
dataset was a model containing lactate, bilirubin, and
PaO2/FiO2 ratio (AUC = 0.89). Model selection using
stepwise regression and ANOVA resulted in a model
Table 2 Glasgow Royal Infirmary (GRI) dataset patient characteristics and univariate analysis
Variable All patients (n = 84) ICU survivor (n = 59) ICU death (n = 25) P value
Age mean (range) 50.2 (29–80) 49.7 (29–80) 51.4 (32–72) 0.55
Gender, male, n (%) 59 (70.2 %) 41 (69.5 %) 18 (72.0 %) 1.00
SIMD category 0.44
1–2 (deprived), n (%) 68 (81.0 %) 46 (78.0 %) 22 (88.0 %)
3–5 (non-deprived), n (%) 16 (19.0 %) 13 (22.0 %) 3 (12.0 %)
Alcoholic aetiology, n (%) 70 (83.3 %) 48 (81.3 %) 22 (88.0 %) 0.54
Encephalopathy, any, n (%) 29 (34.5 %) 19 (32.2 %) 10 (40.0 %) 0.66
Ascites, any, n (%) 35 (41.7 %) 22 (37.3 %) 13 (52.0 %) 0.31
Sodium, mmol/L, mean (range) 136.4 (113.0–151.0) 136.7 (113.0–151.0) 135.7 (128.0–147.0) 0.52
Potassium, mmol/L, mean (range) 4.1 (2.6–7.0) 4.0 (2.6–7.0) 4.3 (2.9–5.9) 0.27
Urea, μmol/L, median (IQR) 8.1 (4.1–12.7) 7.7 (4.4–12.1) 9.2 (4.0–14.5) 0.44
Lactate, mmol/L, median (IQR) 1.9 (1.3–2.7) 1.7 (1.2–2.2) 4.1 (2.0–8.0) <0.001
Creatinine, μmol/L, median (IQR) 81.5 (57.8–158.8) 75.0 (57.5–138.5) 144.0 (69.0–199.0 ) 0.056
WCC, × 109/L, mean (range) 13.6 (0.8–41.7) 13.6 (0.8–36.4) 13.6 (1.5–41.7) 0.99
Bilirubin, μmol/L, median (IQR) 45.5 (22.3–106.8) 33.0 (18.0–76.5) 71.0 (40.0–182.0) 0.0048
PT ratio, median (IQR) 1.5 (1.2–2.0) 1.5 (1.2–1.8) 1.8 (1.5–2.5) 0.012
Albumin, g/L, mean (range) 21.8 (8.0–79.0) 22.6 (8.0–79.0) 19.8 (10.0–33.0) 0.14
Platelets, × 109/L, mean (range) 138.5 (6.0–487.0) 145.4 (25.0–487.0) 122.2 (6.0–371.0) 0.31
PaO2, kPa, median (IQR) 12.4 (9.9–18.1) 12.5 (9.8–19.2) 12.1 (10.0–15.8) 0.65
PaO2/FiO2 ratio, median (IQR) 21.8 (12.8–35.6) 24.5 (14.8–38.6) 15.8 (11.7–25.3) 0.032
APACHE II, mean (range) 23.5 (2.0–47.0) 21.5 (2.0–39.0) 28.3 (14.0–47.0) <0.001
SOFA, mean (range) 9.7 (3.0–20.0) 8.6 (3.0–15.0) 12.3 (4.0–20.0) <0.001
MELD, median (IQR) 19.0 (13.3–25.0) 16.0 (12.0–21.0) 25.0 (20.0–30.0) <0.001
UKELD, median (IQR) 52.0 (47.3–58.0) 51.0 (47.0–53.0) 58 (50.0–61.0) 0.0016
CTP, median (IQR) 9.0 (7.3–11.0) 9.0 (7.0–11.0) 11.0 (9.0–13.0) 0.012
CTP + L, median (IQR) 11.0 (9.0–14.3) 10.0 (9.0–12.5) 15.0 (13.0–19.0) <0.001
CLIF-SOFA, median (IQR) 10.0 (7.0–12.3) 9.0 (6.0–11.0) 12.0 (10.0–14.0) <0.001
RFH, median (IQR) 0.41 (–0.93–2.00) −0.52 (−1.64–0.73) 2.12 (0.52–3.14) <0.001
SIMD Scottish Index of Multiple Deprivation, WCC white cell count, PT prothrombin time, PaO2, arterial partial pressure of oxygen, FiO2, inspired oxygen fraction,
APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, MELD model of end-stage liver disease, UKELD United
Kingdom model for end-stage liver disease, CTP Child-Turcotte Pugh, CTP + L Child-Turcotte Pugh + lactate, CLIF-SOFA chronic liver failure sequential organ failure
assessment, RFH Royal Free Hospital score
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containing lactate, bilirubin, and PaO2/FiO2 ratio being
selected as the optimum (AUC = 0.89). Odds ratios from
this model were 1.89 (95 % CI 1.37 − 2.92, p = <0.001)
for each mmol/L increase of lactate, 1.01 (95 % CI 1.00–
1.01, p = 0.041) for each μmol/L increase in bilirubin,
and 0.96 (95 % CI 0.92–1.00, p = 0.062) for each kPa in-
crease in PaO2/FiO2 ratio for predicting ICU outcome.
A model was produced using the Glasgow data, based
on independent predictors of outcome from the London
data consisting of PaO2/FiO2 ratio, PT ratio, and urea,
which performed poorly compared to all other models,
with an AUC of 0.73. All other models produced using
the Glasgow dataset had an AUC >0.8.
The above process was repeated for the London data-
set, where models were produced by binary logistic re-
gression and compared using ROC curves. The most
predictive model for the London dataset was a combin-
ation of PaO2/FiO2 ratio, PT ratio, and urea obtaining
an AUC of 0.78. No model based on the London dataset
had an AUC >0.8. Based on stepwise regression analysis
and ANOVA, a model containing lactate and PT ratio
performed best in the London dataset. Odds ratios for
predicting ICU outcome using this model were 1.13
(95 % CI 1.02–1.27, p = 0.032) for each mmol/L increase
in lactate, and 2.17 (95 % CI 1.20–4.53, p = 0.021) for
each increment in PT ratio.
A model was produced using the London data, based on
the independent predictors of outcome from the Glasgow
data, consisting of lactate, bilirubin, and PaO2/FiO2 ratio.
This model performed well compared to all others, with
an AUC of 0.76. This is similar to AUC for the RFH and
CTP + L scoring tools in this cohort of patients.
Table 3 London Dataset patient characteristics and univariate analysis
Variable All patients (n = 115) ICU survivor (n = 72) ICU death (n = 43) P value
Age, mean (range) 50.9 (22.0–82.0) 50.0 (28.0–71.0) 52.44 (22.0–82.0) 0.30
Gender, male, n (%) 78 (67.8 %) 51 (70.8 %) 27 (62.8 %) 0.49
Ascites, any, n (%) 47 (40.9 %) 23 (31.9 %) 24 (55.8 %) 0.023
Sodium, mmol/L, median (IQR) 137.0 (133.0–142.0) 138.0 (133.8–142.0) 137.0 (130.5–140.5) 0.34
Potassium, mmol/L, mean (range) 4.2 (1.9–6.8) 4.1 (1.9–6.8) 4.3 (1.9–6.4) 0.17
Urea, μmol/L, median (IQR) 7.5 (4.3–14.5) 6.7 (4.2–11.6) 10.3 (4.7–15.2) 0.086
Lactate, mmol/L, median (IQR) 2.4 (1.5–4.8) 1.9 (1.3–3.1) 3.9 (2.2–6.8) <0.001
Creatine, μmol/L, median (IQR) 86.0 (56.0–164.5) 67.5 (52.0–135.2) 112.0 (75.5–180.0) 0.051
WCC, × 109/L, mean (range) 12.5 (0.7–35.5) 12.7 (1.8–35.5) 12.1 (0.7–31.4) 0.68
Bilirubin, μmol/L, median (IQR) 40.0 (16.0–102.0) 28.0 (15.0–82.3) 60.0 (23.0–197.5) 0.027
PT ratio, median (IQR) 1.5 (1.2–2.0) 1.4 (1.2–1.7) 1.9 (1.5–2.2) <0.001
Albumin, g/L median (IQR) 22.0 (18.0–27.5) 19.0 (16.5–27.5) 21.0 (17.0–27.0) 0.16
Platelets, × 109/L, median (IQR) 120.0 (67.0–215.0) 122.0 (80.0–235.0) 116.0 (46.5–174.0) 0.11
PaO2, kPa, median (IQR) 12.1 (9.8–17.5) 12.9 (10.1–19.1) 11.1 (9.7–13.4) 0.11
PaO2/FiO2 ratio, mean (range) 30.2 (6.0–77.0) 34.0 (7.0–77.0) 23.9 (6.0–59.0) 0.0011
Arterial pH, median (IQR) 7.32 (7.25–7.41) 7.34 (7.26–7.40) 7.31 (7.21–7.42) 0.34
Bicarbonate, mmol/L, mean (range) 20.9 (7.3–35.2) 21.3 (7.7–31.1) 20.2 (7.3–35.2) 0.33
MCV, fL, mean (range) 97.2 (80.0–124.0) 96.4 (80.0–124.0) 98.5 (82.9–119.0) 0.25
Haemocrit, median (IQR) 0.29 (0.24–0.34) 0.29 (0.24–0.34) 0.29 (0.24–0.33) 0.80
APACHE II, mean (range) 16.9 (5.0–29.0) 15.4 (5.0–27.0) 19.4 (9.0–29.0) <0.001
SOFA, mean (range) 6.4 (0.0–14.0 ) 5.4 (0.0–13.0) 8.0 (2.0–14.0) <0.001
MELD, median (IQR) 18.0 (12.0–24.0) 14.0 (9.8–20.0) 23.0 (17.5–26.0) <0.001
UKELD, median (IQR) 51.0 (46.0–56.0) 48.0 (44.8–55.3) 54.0 (50.0–59.5) <0.001
CTP, median (IQR) 10.0 (8.0–11.0) 9.0 (8.0–11.0) 11.0 (9.5–11.0) <0.001
CTP + L, median (IQR) 13.0 (10.0–16.0) 11.5 (9.0–14.0) 15.0 (13.0–18.0) <0.001
CLIF-SOFA, median (IQR) 10.0 (7.0–12.0) 9.0 (7.0–12.0) 12.0 (11.0–14.0) <0.001
RFH, median (IQR) −0.50 (−3.27–1.34) −1.60 (−3.78–0.00) 1.29 (−0.27–2.65) <0.001
WCC white cell count, PT prothrombin time, PaO2, arterial partial pressure of oxygen, FiO2, inspired oxygen fraction, MCV mean corpuscular volume, APACHE II
acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, MELD model of end-stage liver disease, UKELD United Kingdom model
for end-stage liver disease, CTP Child-Turcotte Pugh, CTP + L Child-Turcotte Pugh + lactate, CLIF-SOFA chronic liver failure sequential organ failure assessment,
RFH Royal Free Hospital score
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Goodness-of-fit of regression models
In order to determine the usefulness of the statistical
models, goodness-of-fit testing was undertaken for both
the Glasgow models by applying them to the London
dataset, and for the London models by applying them to
the Glasgow dataset. The Chi squared goodness-of-fit
test was used for all models and phi coefficients
compared.
Collecting encephalopathy grade for the CTP score
When the CTP and CTP + L scores were compared
in the Glasgow dataset with and without encephalop-
athy scores, results showed that there was no statis-
tically significant difference between collecting and
not collecting pre-intubation encephalopathy scores,
either with the original CTP score (p = 0.12) or the
modified score CTP + L (p = 0.52). Therefore enceph-
alopathy scores do not significantly influence the CTP
or CTP + L scores, and it may be unnecessary to
collect these.
Combined performance of the RFH score and CTP + L
score
As the RFH score and CTP + L scores were the best per-
forming tools in both datasets, the datasets were com-
bined to create a cohort of 199 patients. ROC curves for
the RFH and CTP + L score were produced and are
shown in Fig. 1. Both scores performed well in this com-
bined dataset with the CTP + L score having an AUC of
0.79, and the RFH score an AUC of 0.78. There was no
statistically significant difference between the ROC
curves (p = 0.92).
Discussion
This paper aimed to validate the use of the CTP + L as a
method of predicting ICU outcome in patients with cir-
rhosis admitted to a general ICU. The CTP + L and RFH
scoring tools performed similarly in the Glasgow dataset
and both performed significantly better than the existing
CTP score. When applied to the London dataset to val-
idate the tool, the CTP + L tool performed well but
failed to reach the clinically useful AUC of 0.8, which is
commonly reported in the literature[10]. The CTP + L
tool was more predictive than the CLIF-SOFA score in
both datasets.
Mortality rates in the Glasgow and London datasets
were similar, with ICU mortality being 30 % and 37 %
for the Glasgow and London datasets, respectively, and
the hospital mortality the same in both datasets at 46 %.
These values are lower than the 48 % and 58 % weighted
mean values reported in the literature for ICU and hos-
pital mortality [5]. The SOFA and APACHE II scores
were lower in the London dataset than in the Glasgow
dataset. These are validated scores for measuring the se-
verity of illness in ICU patients, with higher scores indi-
cating increased severity of illness and greater
probability of mortality [22, 23, 29]. The difference in
these scores between the two datasets may reflect a dif-
ference in admission criteria between the different ICUs.
This difference may also reflect the reduced odds ratio
associated with lactate in the two datasets, with higher
arterial lactate concentration reported within the litera-
ture [30, 31] to be associated with higher APACHE II
scores and mortality. Future work in this area should ex-
plore ICU admission criteria for cirrhosis patients to
help understand the care trajectory for this patient
cohort.
Although arterial lactate concentration on admission
was an independent predictor of ICU mortality in both
datasets, the odds ratio for lactate predicting ICU mor-
tality was higher within the Glasgow dataset than the
London dataset (odds ratio 1.89 vs 1.13, respectively).
Other published papers in this field [16, 17] report odds
ratios for lactate higher than that in the London dataset.
Table 4 Receiver operating characteristic curve analysis
Scoring tool AUC 95 % CI Cut point Sensitivity Specificity
Glasgow dataset
RFH 0.84 0.75–0.93 0.41 0.88 0.67
CTP + L 0.83 0.73–0.93 13.5 0.72 0.84
CLIF-SOFA 0.79 0.69–0.89 11.5 0.72 0.78
MELD 0.77 0.66–0.88 16.5 0.88 0.58
SOFA 0.76 0.65–0.87 9.5 0.80 0.61
APACHE II 0.73 0.61–0.85 25.5 0.60 0.76
UKELD 0.72 0.60–0.84 54.5 0.68 0.81
CTP 0.67 0.55–0.80 10.5 0.52 0.74
London dataset
RFH 0.77 0.67–0.86 0.14 0.73 0.75
CTP + L 0.75 0.66–0.84 12.5 0.79 0.63
CLIF-SOFA 0.74 0.65–0.84 10.5 0.76 0.67
SOFA 0.71 0.62–0.81 5.5 0.77 0.61
APACHE II 0.71 0.61–0.80 14.5 0.81 0.50
MELD 0.70 0.60–0.80 20.5 0.63 0.76
UKELD 0.69 0.60–0.79 49.5 0.79 0.58
CTP 0.68 0.59–0.78 8.5 0.88 0.47
Cut points and associated sensitivity and specificity were determined by the
Youden’s index obtained from receiver operating characteristic curves. AUC
area under the curve, APACHE II acute physiology and chronic health
evaluation II, SOFA sequential organ failure assessment, MELD model of
end-stage liver disease, UKELD United Kingdom model for end-stage liver
disease, CTP Child-Turcotte Pugh, CTP + L Child-Turcotte Pugh + lactate,
CLIF-SOFA chronic liver failure sequential organ failure assessment, RFH Royal
Free Hospital score
Campbell et al. Critical Care  (2015) 19:364 Page 6 of 9
Univariate analysis of the Glasgow dataset demon-
strated that on admission, lactate, bilirubin, PaO2/FiO2
ratio, and PT ratio were significant predictors of ICU
mortality. These significant predictors were also signifi-
cant predictors within the London dataset, and other
published literature [17]. It was also found in the
London dataset that the presence of ascites was a signifi-
cant predictor of mortality, which was not found in the
Glasgow dataset. The significance of lactate, bilirubin
and PT ratio as predictors of mortality are logical from a
physiological point of view, with elevated lactate demon-
strating insufficient oxygen delivery to tissues, or the
failure of the liver to metabolise lactate, or both [32]. El-
evated bilirubin and PT ratio may represent failure of
the liver to metabolise waste products and perform its
synthetic function [33, 34].
The RFH score was designed and validated for predict-
ing hospital mortality within a liver transplant centre but
not for predicting mortality in a general ICU population
[18]. The results of this study validate the use of the
RFH score as a prognostic scoring tool for predicting
ICU mortality, as demonstrated by its performance in
both the Glasgow and London datasets. Although the
performance of the RFH is similar to that of the CTP +
L score, the RFH is more complex to calculate. Due to
the complexity of the calculation, and the requirement
to separately calculate the number of failing organ sys-
tems, it is clear that this tool is designed for calculation
on a computer, which may not be available at the pa-
tient’s bedside.
The CTP + L score, however, can be calculated quickly
at the patient’s bedside using simple criteria to score 1,
2, or 3 points for each variable, and adding the raw value
of the serum arterial lactate to this score, as can be seen
in Table 1. CTP + L and RFH scores both predict ICU
mortality to a similar degree. However, due to its simpli-
city, the CTP + L may be a more practical and versatile
tool for evaluating patients quickly for admission to the
ICU.
From multivariable analysis in the Glasgow dataset,
the model that produced the best AUC was that contain-
ing lactate, bilirubin and PaO2/FiO2 ratio (AUC = 0.89).
Fig. 1 Receiver operating characteristic (ROC) curve showing the performance of the Child-Turcotte Pugh plus lactate (CTP + L) and Royal Free
Hospital (RFH) scoring tools in predicting ICU mortality in the combined Glasgow and London datasets. AUC area under the curve
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This model also performed well in the London cohort of
patients, producing an AUC of 0.76, which is compar-
able to that of the RFH and CTP + L, as can be seen in
Table 4. This same model was selected as the optimum
model within the Glasgow dataset based on ANOVA.
This suggests that a scoring tool comprising only these
factors could be used to predict ICU mortality. This
would need to be validated in a larger cohort of patients
in order to test its usefulness.
No scoring tool or statistical model from the London
dataset reached the clinically useful AUC of 0.8. This is
in contrast to the GRI dataset, where all models except
one performed with an AUC >0.8. This suggests that pa-
tients from within the London dataset have fewer pre-
dictive variables compared with the Glasgow dataset, or
that the predictive variables within the London cohort
were not recorded and therefore not included in this
analysis. Goodness-of-fit tests show that although the
AUC was lower when the models were applied to the
London dataset, the models were still predictive of ICU
mortality.
This paper demonstrates that collecting pre-intubation
hepatic encephalopathy scores does not increase the pre-
dictive values of the CTP or CTP + L scoring tools. Both
datasets were combined to compare the performance of
the two most predictive scoring tools: the RFH and CTP
+ L. This ROC curve (Fig. 1) shows that these two tools
are similarly matched in predicting ICU outcome in the
combined cohort of 199 patients.
Limitations
Validation of the CTP + L in the London datasets is
limited, as the London dataset does not contain pre-
intubation encephalopathy score, which is a key compo-
nent of the CTP + L tool. This lack of pre-intubation
encephalopathy score limits the ability to show that en-
cephalopathy score is not required as part of the CTP +
L score, and further evidence from another centre with
pre-intubation encephalopathy score would be required
to prove this conclusively. Both hepatic encephalopathy
grade and ascites are subjective in nature and this makes
them difficult to assess objectively and apply as part of a
scoring tool. Additionally, clinical values for the scoring
tools at admission were taken as soon as possible follow-
ing admission, but in some cases this was delayed by a
few hours. This variability in time until first available test
results from admission may affect the predictive ability
of the scoring tools. The use of first available clinical
values does not account for any lead-time bias that may
occur. Albumin is routinely administered for patients
with cirrhosis as part of current guidelines, however any
albumin administered before ICU admission would
affect the utility of albumin as a predictive measure of
ICU outcome.
Conclusion
It is known that patients admitted to ICU with cirrhosis
have high mortality, however, the mortality rates within
these cohorts are more favourable than those published
in the literature. The CTP + L and RFH scoring tools are
validated prognostic scoring tools for predicting ICU
mortality in patients with cirrhotic liver disease admitted
to a general ICU department. Collecting hepatic enceph-
alopathy scores is not required for the CTP or CTP + L
score, however, this would need to be validated on an
external cohort of patients.
Key messages
 The CTP + L and RFH scoring tools are validated
prognostic scoring tools for patients with cirrhosis
admitted to a general ICU
 Mortality rates in these cohorts are more favourable
than those published in the literature
 Collecting hepatic encephalopathy scores may not
be necessary for the CTP or CTP + L score in
patients admitted to the general ICU, although this
requires external validation
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